Xenetic Biosciences, Inc , a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
infoXenetic Biosciences is a micro cap stock with a total market cap of 5.70M.
infoThey trade on the NASDAQ and had their IPO 7 years and 1 month ago.
infoXenetic Biosciences currently employs 4 people.
infoAs of Wednesday, Aug 23 2023, Xenetic Biosciences’s share price is $3.72.
News Relating to Xenetic Biosciences
Zacks Investment Research
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Friday Aug 11 2023 at 10:47
Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.90 per share a year ago.
Accesswire
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Thursday Mar 16 2023 at 08:05
Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / March 16, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that it will participate in the Virtual Investor NETs in Cancer Spotlight Event on Wednesday, March 29, 2023 at 11:00 AM ET. For the roundtable discussion, Jeffrey F.
Accesswire
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Thursday Jan 05 2023 at 08:05
Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET. A live video webcast of the presentation will be available on the Events page in the Investors section of the Company’s website (www.XeneticBio.com).
Accesswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Wednesday Sep 07 2022 at 08:05
FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C.
Proactive Investors
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
Tuesday Aug 02 2022 at 10:07
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition’s Nu.Q NETs Test and Xenetic’s DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.
Accesswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
Wednesday May 18 2022 at 08:15
Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C.
Accesswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Wednesday Sep 08 2021 at 08:00
FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C.
PennyStocks
5 Penny Stocks Analysts Say To Buy With Targets Up To 300%
Wednesday Aug 18 2021 at 11:41
Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
InvestorPlace
Short Squeeze Stocks: NAOV, AHPI and 3 Others Experts Think Are Ready to Pop
Monday Aug 16 2021 at 15:41
Looking for a list of the best short squeeze stocks available? We’ve got you covered with Fintel’s insight into the topic today.
Accesswire
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
Friday Aug 13 2021 at 08:05
Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies Strong royalty growth with PolyXen® platform technology Bolstered cash position with recently completed $12.5 million private placement FRAMINGHAM, MA / ACCESSWIRE / August 13, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the second quarter of 2021 and provided a corporate update. “Over the course of the second quarter, we continued to execute our innovative and differentiated XCART program, and the technical progress we’ve accomplished brings us closer to the critical milestone of conducting IND-enabling studies in the United States.
Pulse2
Xenetic Biosciences Shares Increase Over 37% Intraday: Why It Happened
Thursday Aug 12 2021 at 11:52
The shares of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 37% during intraday trading. This is why it happened.
Pulse2
XBIO Stock Increased 65.11%: Details You Should Know
Friday Jul 30 2021 at 08:31
The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by 65.11% yesterday. This is why it happened.
Accesswire
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
Wednesday Jul 28 2021 at 14:00
FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock (or common stock equivalents) at a purchase price per share of $2.70, priced at-the-market under Nasdaq rules. The gross proceeds to Xenetic totaled approximately $12.5 million before deducting placement agent fees and other offering expenses.
InvestorPlace
XBIO Stock: Xenetic Soars on Private Placement Announcement
Monday Jul 26 2021 at 13:53
XBIO stock is continuing a heck of a week. Just days after it was boosted by Takeda’s expansion news, it’s looking at a big private sale.
PennyStocks
Biotech Penny Stocks Are Heating Up, Here’s 3 To Watch Right Now
Monday Jul 26 2021 at 12:37
Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here’s 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pulse2
XBIO Stock Increases Over 30% Pre-Market: Why It Happened
Monday Jul 26 2021 at 07:57
The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 30% pre-market. This is why it happened.
Accesswire
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
Monday Jul 26 2021 at 07:00
FRAMINGHAM, MA / ACCESSWIRE / July 26, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase of 4,629,630 shares of its common stock (or common stock equivalents) at a purchase price per share of $2.70, in a private placement priced at-the-market under Nasdaq rules. Additionally, Xenetic has also agreed to issue to the investor warrants to purchase up to 4,629,630 shares of common stock.
InvestorPlace
XBIO Stock: Xenetic Soars on Takeda Expansion News
Friday Jul 23 2021 at 13:24
XBIO stock is racing to the moon today, as Takeda Pharmaceuticals makes an announcement that will see higher demand for Xenetic products. The post XBIO Stock: Xenetic Soars on Takeda Expansion News appeared first on InvestorPlace.
PennyStocks
3 Penny Stocks That Exploded Today, One Up 144%
Friday Jul 23 2021 at 12:30
These penny stocks shot up substantially today; worth it or not? The post 3 Penny Stocks That Exploded Today, One Up 144% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pulse2
XBIO Stock Increases Over 15% Pre-Market: Why It Happened
Friday Jul 23 2021 at 08:06
The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 15% pre-market. This is why it happened.
Pulse2
XBIO Stock Increased 27.96% After Hours: Why It Happened
Friday Jul 23 2021 at 01:27
The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased 27.96% after hours. Why It Happened The post XBIO Stock Increased 27.96% After Hours: Why It Happened appeared first on Pulse 2.0.
Pulse2
XBIO Stock Increases Over 59% Intraday: Details
Tuesday Jul 13 2021 at 14:15
The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 59% during intraday trading. These are some details you should know.
PennyStocks
3 Penny Stocks to Watch Making Big Gains Today, One Up 130%
Tuesday Jul 13 2021 at 13:57
Are these volatile penny stocks worth watching after big gains today? The post 3 Penny Stocks to Watch Making Big Gains Today, One Up 130% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pulse2
XBIO Stock Price: Over 20% Increase Pre-Market Details
Monday Jun 14 2021 at 05:23
The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 20% pre-market. These are the details.
Accesswire
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
Monday May 10 2021 at 08:30
Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present the Q2 Virtual Investor Summit on Tuesday, May 18th at 3:30 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
Pulse2
XBIO Stock Price Increased Over 5% Pre-Market: Why It Happened
Monday Mar 29 2021 at 09:11
The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) increased by over 5% pre-market. This is why it happened.
Accesswire
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)
Monday Mar 29 2021 at 08:05
– Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States – Study will evaluate the XCART process of neoantigen identification and generation of tumor-specific CAR T candidates, in a real-world clinical setting FRAMINGHAM, MA / ACCESSWIRE / March 29, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced it has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART. “The start of this study represents an important step forward in our preclinical development program, and we look forward to evaluating the XCART platform applied to tumor samples from NHL patients currently under evaluation or in treatment at the study site.
Accesswire
Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
Wednesday Mar 17 2021 at 08:00
Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging PolyXen® platform technology FRAMINGHAM, MA / ACCESSWIRE / March 17, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the fourth quarter and full year 2020, and provided a corporate update. “Notwithstanding the challenges presented by the COVID-19 pandemic, 2020 was a year of significant progress for the Company, including the establishment of partnerships and academic collaborations and advancement in our development efforts, in particular with respect to CAR design and model cell line development, as well as the strengthening of our financial position.
Accesswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
Wednesday Mar 03 2021 at 08:05
FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.
Accesswire
Xenetic Biosciences, Inc. to Present at NobleCon17
Thursday Jan 14 2021 at 08:00
FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET. A high-definition, video webcast will be available at the time of the Company’s presentation to those registered to attend the event.
Xenetic Biosciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Xenetic Biosciences’s Altman Z-score is -17.0 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Xenetic Biosciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Xenetic Biosciences.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Xenetic Biosciences’s Income Quality of 0.73 is in line with its Industry Group of 0.69 (5.8% greater)
Xenetic Biosciences’s Income Quality of 0.73 is in line with its Major Industry Group of 0.71 (2.8% greater)
Xenetic Biosciences’s Income Quality of 0.73 is in line with its Sector of 0.75 (-2.7% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Xenetic Biosciences’s Current Ratio of 13.82 is greater than its Industry Group of 4.76 (190.3% greater)
Xenetic Biosciences’s Current Ratio of 13.82 is greater than its Major Industry Group of 4.32 (219.9% greater)
Xenetic Biosciences’s Current Ratio of 13.82 is greater than its Sector of 2.6 (431.5% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.43 & -1.27)
Cannot compare a negative PE Ratio (-1.43 & -1.1)
Cannot compare a negative PE Ratio (-1.43 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Xenetic Biosciences’s PB Ratio of 0.48 is lower than its Industry Group of 1.34 (-64.2% lower)
Xenetic Biosciences’s PB Ratio of 0.48 is lower than its Major Industry Group of 1.4 (-65.7% lower)
Xenetic Biosciences’s PB Ratio of 0.48 is lower than its Sector of 1.62 (-70.4% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Xenetic Biosciences’s ROE of -0.34 is greater than its Industry Group of -0.44 (22.7% greater)
Xenetic Biosciences’s ROE of -0.34 is greater than its Major Industry Group of -0.38 (10.5% greater)
Xenetic Biosciences’s ROE of -0.34 is lower than its Sector of -0.03 (-1033.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Xenetic Biosciences’s ROCE of -0.38 is in line with its Industry Group of -0.42 (9.5% greater)
Xenetic Biosciences’s ROCE of -0.38 is in line with its Major Industry Group of -0.37 (-2.7% lower)
Xenetic Biosciences’s ROCE of -0.38 is lower than its Sector of -0.04 (-850.0% lower)
Derived from SEC.GOV filing dataopen_in_new